Welcome to our dedicated page for Cannabix Technol news (Ticker: BLOZF), a resource for investors and traders seeking the latest updates and insights on Cannabix Technol stock.
Cannabix Technologies Inc. develops marijuana and alcohol breath-testing technologies for workplace safety, law enforcement, and other safety-sensitive settings. Company news centers on the Marijuana Breath Test, or MBT, including its Breath Collection Unit and single-use Breath Cartridges used to collect breath samples for laboratory analysis of recent cannabis use.
Recurring updates include commercial rollout activity, deliveries through authorized resellers, product validation, regulatory and compliance testing for device hardware, and distribution or education efforts with testing-industry partners. News also covers the company’s work with Omega Laboratories on analytical methods for detecting cannabinoids in breath samples using LC-MS-based testing.
Cannabix Technologies (OTCID: BLOZF) announced a second sales agreement to deliver an additional BreathLogix unmanned alcohol screening unit to an existing European maritime customer on Dec 2, 2025.
The device will integrate with the cloud-based BreathLogix Connect platform (powered by Amazon Web Services) for real-time alerts, centralized data management and reporting, and will include facial recognition for crew identification. BreathLogix supports multiple workplace testing scenarios and is listed on the U.S. Federal Register Conforming Products List (NHTSA). The system uses a patent-pending pre-calibrated sensor cartridge to reduce maintenance needs.
Cannabix Technologies (OTC: BLOZF) announced that the United States Patent and Trademark Office granted patent No. 18/1729,658 on Oct 27, 2025 for a “Contact-Free Breath Analysis Device and Method.”
The patent covers Cannabix's dual‑mode contactless and mouthpiece breath capture and analysis used in its BreathLogix platform, enabling unmanned devices, real‑time visual feedback, adaptive airflow control, and compact modular designs for vehicles, workplaces, public kiosks, law enforcement, workplace safety, and public health monitoring.
Cannabix Technologies (OTC: BLOZF) announced delivery of its BreathLogix alcohol screening device to an oil and gas transportation services company in northern Alberta on October 16, 2025.
The unmanned system records BrAC/BAC, captures a user photo, logs results on a BreathLogix Connect web portal, sends real-time alerts by SMS and e-mail, and supports integration with access control and fleet systems. The Workplace Series has been added to the NHTSA Conforming Products List (CPL) for breath alcohol screen devices.
On October 15, 2025, the company signed a three-month marketing services agreement with Black Swan Solutions dba VHLA Media for C$100,000 plus GST; no securities will be issued as payment.
Cannabix Technologies (OTC:BLOZF) has achieved its first sale of the BreathLogix unmanned alcohol screening technology to a European maritime shipping company. The system, which includes cloud-based "BreathLogix Connect" platform powered by AWS, features facial recognition and provides real-time alerts for crew safety monitoring.
The announcement follows the company's first commercial production run and recent NHTSA approval for the BreathLogix "Workplace Series" device. The technology delivers precise BAC measurements, enables real-time test reporting, and features patent-pending pre-calibrated sensor cartridge technology for easy maintenance. The system can integrate with various access control systems and supports multiple testing scenarios including pre-access, start-of-shift, and random testing.
Cannabix Technologies (OTC:BLOZF), a developer of marijuana and alcohol breath testing devices, announced its participation in the inaugural cannabis breathalyzer workshop hosted by the U.S. National Institute of Standards and Technology (NIST). The workshop, titled "Building a Path Forward for Meaningful Cannabis Breathalyzer Realization," will be held at NIST's Colorado facilities in September.
The company will showcase its Marijuana Breath Test (MBT) technology, which detects recent cannabis use through delta-9-tetrahydrocannabinol (Δ9-THC) identification. The system features proprietary Breath Collection Unit (BCU) and Breath Cartridge (BC) technologies designed to collect and preserve breath samples for analysis using LC-MS methods.
Cannabix Technologies (OTC:BLOZF) announced its participation in the upcoming NSC Safety Congress & Expo in Denver, Colorado from September 15-17, 2025. The company will showcase two key products alongside distribution partner Alco Prevention Canada: the Cannabix Marijuana Breath Test (MBT) for recent THC use detection and the BreathLogix alcohol screening devices.
The BreathLogix system features real-time BAC testing with photo identification, SMS/email alerts, and integration capabilities with various access control systems. Notably, the BreathLogix "Workplace Series" device received NHTSA approval and was added to the U.S. Federal Register Conforming Products List for breath alcohol screening devices in May.
Cannabix Technologies (OTC:BLOZF) has delivered multiple Marijuana Breath Test (MBT) units to Omega Laboratories in Ohio, marking a significant step in their commercialization efforts. The technology includes proprietary Breath Collection Units (BCU) and Breath Cartridges (BC) designed to detect recent cannabis use through delta-9-tetrahydrocannabinol (Δ9-THC) detection.
The initial delivery comprises 200 Breath Cartridges and several BCUs. The companies are collaborating on manufacturing, marketing, distribution, and logistics for the MBT. Omega Laboratories, an international leader in forensic drug testing with ISO/IEC 17025 accreditation, has already delivered a Validation Packet for their Laboratory Developed Test Method to test delta-9 THC analytes.
Cannabix Technologies (OTC:BLOZF) has appointed William (Bill) R. Corl, CEO of Omega Laboratories, to its Board of Directors. Corl brings over 26 years of experience in diagnostic testing and technology solutions, with significant expertise in advancing drug screening industry standards.
The appointment strengthens the existing strategic partnership between Cannabix and Omega Laboratories, established in May 2024, focused on commercializing the company's Marijuana Breath Test (MBT) technology. Omega has already integrated Cannabix Breath Cartridges into its testing protocols and both companies are collaborating on marketing, distribution, manufacturing, and logistics for the MBT.
Cannabix Technologies (OTC:BLOZF) has received a notice of allowance from the Canadian Intellectual Property Office (CIPO) for its patent application titled "Contact-Free Breath Analysis Device and Method." This follows a similar notice from the U.S. Patent and Trademark Office for the same technology.
The patent covers dual-mode contactless breath capture and analysis technology that can be integrated into vehicles, workplaces, and public kiosks. The system features unmanned testing capabilities, real-time feedback, and intelligent airflow adjustment mechanisms, making it particularly valuable for law enforcement, workplace safety, and public health monitoring applications.
Cannabix Technologies (OTC:BLOZF) has initiated its first production run of BreathLogix alcohol screening devices, partnering with Price Electronics as their contract manufacturer. Price Electronics, with their 28,000 square foot facility in Winnipeg, brings significant credentials including ISO 13485, ISO9001, and IPC certifications.
The BreathLogix "Workplace Series" device has received National Highway Traffic Safety Association approval and has been added to the U.S. Federal Register Conforming Products List for breath alcohol screening devices. Additionally, the company has secured an exclusive distribution agreement with Breathalyser Sales & Service Pty Ltd. for Australia, New Zealand, and the Pacific Islands.